Welcome to our dedicated page for Soligenix SEC filings (Ticker: SNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Investing in Soligenix’s orphan-drug pipeline and biodefense vaccines means parsing filings packed with clinical protocols, government contracts, and stock issuances. Finding how a new HyBryte® study moves revenue, or when ThermoVax® funding converts to cash, takes time investors rarely have.
Stock Titan solves that problem. Our AI turns a dense Soligenix annual report 10-K simplified into plain language, highlights Soligenix 8-K material events explained moments after EDGAR posts, and links every Soligenix insider trading Form 4 transactions entry to intuitive charts. Ask for “Soligenix SEC filings explained simply,” “Soligenix earnings report filing analysis,” or “understanding Soligenix SEC documents with AI” and get answers—not page counts. Real-time alerts cover the next Soligenix quarterly earnings report 10-Q filing and stream Soligenix Form 4 insider transactions real-time so you never miss a disclosure.
Use this hub to:
- Monitor Soligenix executive stock transactions Form 4 before market close
- Compare R&D and grant revenue trends across quarters with AI-generated tables
- Review the Soligenix proxy statement executive compensation section without sifting through legal jargon
AI-powered summaries, expert commentary, comprehensive coverage of every form, and real-time updates mean you spend minutes—not hours—finding what matters inside Soligenix filings.
Form 4 filing reveals that Anthony Gregg Lapointe, Director of Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:
- Granted 17,647 stock options to purchase common stock
- Exercise price set at $1.70 per share
- Options expire on June 20, 2035
- Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026
This grant represents standard director compensation and indicates continued board engagement. The 10-year option term provides long-term alignment with shareholder interests.
Form 4 Filing Details: Jerome B. Zeldis, Director of Soligenix (SNGX), reported the acquisition of stock options on June 20, 2025. The insider was granted 17,647 stock options with an exercise price of $1.70 per share.
The options have a 10-year term expiring on June 20, 2035, and will vest in four equal installments on:
- September 20, 2025
- December 20, 2025
- March 20, 2026
- June 20, 2026
This equity-based compensation grant aligns the director's interests with shareholders through long-term stock ownership potential. The filing was reported within the required SEC timeline, demonstrating compliance with Section 16(a) reporting obligations.
Form 4 filing reveals that Robert J. Rubin, Director at Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:
- Granted 17,647 stock options to purchase common stock
- Exercise price set at $1.70 per share
- Options expire on June 20, 2035
- Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026
This equity compensation grant aligns the director's interests with shareholders through a standard 10-year term and quarterly vesting schedule over one year. The transaction was reported in compliance with SEC Section 16 requirements for insider trading disclosure.
Form 4 filing reveals that Diane L. Parks, Director at Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:
- Granted 17,647 stock options to purchase common stock
- Exercise price set at $1.70 per share
- Options expire on June 20, 2035
- Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026
This stock option grant represents standard director compensation and aligns the director's interests with shareholders through long-term equity incentives. The 10-year exercise period provides significant time value for these options.
Soligenix has filed a Form S-8 to register securities under its 2025 Equity Incentive Plan. The company, headquartered in Princeton, New Jersey, is classified as both a non-accelerated filer and a smaller reporting company.
Key filing incorporations include:
- Annual Report on Form 10-K for FY2024 (filed March 21, 2025)
- Q1 2025 Form 10-Q (filed May 9, 2025)
- Recent Form 8-K filings from February, March, and June 2025
The registration includes comprehensive indemnification provisions for directors and officers under Delaware law, including protection against personal liability for fiduciary duty breaches, except in cases of:
- Breach of duty of loyalty
- Acts not in good faith or involving intentional misconduct
- Unlawful dividend payments or stock repurchases
- Improper personal benefit transactions
FAQ
What is the current stock price of Soligenix (SNGX)?
What is the market cap of Soligenix (SNGX)?
What is the core focus of Soligenix Inc?
How does Soligenix generate revenue?
What are the main business segments of Soligenix?
What therapeutic areas does Soligenix focus on?
How does HyBryte™ differentiate itself in treating CTCL?
What role does intellectual property play for Soligenix?
How is the company supported financially?
What are the key technologies used in Soligenix's vaccine programs?
